A Study of TRB191 in Patients With Extensive-stage Small Cell Lung Cancer
A Phase I, Open-label, Multi-center Study of TRB191 in Patients With Extensive Stage Small Cell Lung Cancer
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity (IG) and preliminary anti-tumor activity and to determine a recommended dose (RD) of TRB191 in patients with extensive-stage small cell lung cancer (ES-SCLC).
研究概览
详细说明
This is a phase I, open-label, multi-center, first-in-human (FIH) study of TRB191 in adult patients with ES-SCLC. The study is comprised of a dose escalation part followed by a dose expansion part in second-line and beyond (2L+) ES-SCLC patients.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名：Novartis Pharmaceuticals
- 电话号码：1-888-669-6682
- 邮箱：novartis.email@novartis.com
研究联系人备份
- 姓名：Novartis Pharmaceuticals
- 电话号码：+41613241111
学习地点
-
-
-
Tel Aviv、以色列、6423906
- 招聘中
- Novartis Investigative Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥ 18 years old
- Histologically or cytologically confirmed and documented ES-SCLC
- Dose escalation: Patients with ES-SCLC and disease progression after one or more chemotherapy regimens (with or without PD-L1 inhibitor) according to the local standard of care (SOC). Prior treatment with a DLL3-targeted therapy is allowed, except in cohorts designed to evaluate TRB191 in patients who are naïve to prior DLL3-targeted therapy
- Dose expansion: Patients with ES-SCLC and disease progression after one or more chemotherapy regimens (with or without PD-L1 inhibitor), according to the local SOC. Patients must have received prior treatment with tarlatamab
Exclusion Criteria:
- Patients with inadequate bone marrow function and/or organ functions with out-of-range laboratory values
- Impaired cardiac function or clinically significant cardiac disease
- Presence of symptomatic central nervous system (CNS) metastases or CNS metastases requiring local therapy or increasing doses of corticosteroids within 2 weeks prior to study entry
- Treatment with anti-cancer therapies prior to the first dose of study treatment within the stated timeframes
- Pregnant or nursing woman, and women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception
Other protocol-defined inclusion/exclusion criteria may apply.
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：不适用
- 介入模型：单组作业
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：TRB191 single agent
Treatment with TRB191 single agent in patients with extensive-stage small cell lung cancer. |
Subcutaneous injection of TRB191 |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Dose intensity
大体时间：Up to approximately 24 months
|
Dose intensity defined as the ratio of actual cumulative dose received and actual duration of exposure. |
Up to approximately 24 months
|
|
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间：Up to approximately 24 months
|
Number of participants with AEs and SAEs, including changes in laboratory values, vital signs and echocardiograms (ECGs) qualifying and reported as AEs. |
Up to approximately 24 months
|
|
Incidence of Dose Limiting Toxicities (DLTs)
大体时间：21 days
|
Number of participants with DLTs. A DLT is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher, unless clearly and incontrovertibly assessed as due to underlying disease, disease progression, or intercurrent illness, that occurs within the first 21 days of treatment with TRB191. Other clinically significant toxicities may be considered DLTs, even if not CTCAE grade 3 or higher. |
21 days
|
|
Frequency of dose interruptions and reductions
大体时间：Up to approximately 24 months
|
Number of participants with dose adjustments (interruptions and reductions as a measure of tolerability. |
Up to approximately 24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Maximum serum concentration (Cmax) of TRB191
大体时间：From pre-dose up to 120 or 240 hours post-dose
|
Pharmacokinetic (PK) parameters based on serum concentrations of TRB191. Cmax will be determined using non-compartmental method(s). |
From pre-dose up to 120 or 240 hours post-dose
|
|
Time to reach maximum serum concentration (Tmax) of TRB191
大体时间：From pre-dose up to 120 or 240 hours post-dose
|
PK parameters based on serum concentrations of TRB191. Tmax will be determined using non-compartmental method(s). |
From pre-dose up to 120 or 240 hours post-dose
|
|
Arean under the serum concentration-time curve (AUC) of TRB191
大体时间：From pre-dose up to 120 or 240 hours post-dose
|
PK parameters based on serum concentrations of TRB191. AUC will be determined using non-compartmental method(s). |
From pre-dose up to 120 or 240 hours post-dose
|
|
Number of participants with anti-drug antibodies (ADA)
大体时间：From baseline (pre-dose) up to approximately 24 months
|
Number of participants with anti-TRB191 antibodies during treatment. |
From baseline (pre-dose) up to approximately 24 months
|
|
Overall Response Rate (ORR) per RECIST v1.1
大体时间：Up to approximately 24 months
|
ORR is defined as the proportion of patients with a best overall response (BOR) of Complete response (CR) or Partial response (PR) as per local review and according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1). |
Up to approximately 24 months
|
|
Disease Control Rate (DCR) per RECIST v1.1
大体时间：Up to approximately 24 months
|
DCR is defined as the proportion of patients with a BOR of CR, PR, or stable disease as per local review and according to RECIST v1.1. |
Up to approximately 24 months
|
|
Duration of Response (DOR) per RECIST v1.1
大体时间：Up to approximately 24 months
|
DOR is the time between the first documented response (CR or PR) and the date of progression as per local review and according to RECIST v 1.1, or death due to any cause. |
Up to approximately 24 months
|
|
Progression-Free Survival (PFS) per RECIST v1.1
大体时间：Up to approximately 24 months
|
PFS is defined as the time from the date of start of treatment to the date of the first documented progression as per local review and according to RECIST v1.1 or death due to any cause. |
Up to approximately 24 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CTRB191A12101
- 2026-526463-37 (注册表标识符：EU CTIS)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
IPD 计划说明
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.